AU2002224321B2 - Lactam compound - Google Patents

Lactam compound Download PDF

Info

Publication number
AU2002224321B2
AU2002224321B2 AU2002224321A AU2002224321A AU2002224321B2 AU 2002224321 B2 AU2002224321 B2 AU 2002224321B2 AU 2002224321 A AU2002224321 A AU 2002224321A AU 2002224321 A AU2002224321 A AU 2002224321A AU 2002224321 B2 AU2002224321 B2 AU 2002224321B2
Authority
AU
Australia
Prior art keywords
methyl
amino
tetrahydro
benzazepin
dihydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002224321A
Other languages
English (en)
Other versions
AU2002224321A1 (en
Inventor
James Abraham Aikins
James Edmund Audia
Lynne Ann Buccilli
Gary Lowell Engel
Thomas Mitchell Koenig
Stacey Leigh Mcdaniel
David Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002224321A1 publication Critical patent/AU2002224321A1/en
Application granted granted Critical
Publication of AU2002224321B2 publication Critical patent/AU2002224321B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cephalosporin Compounds (AREA)
AU2002224321A 2000-11-17 2001-11-02 Lactam compound Ceased AU2002224321B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17
US60/249,656 2000-11-17
PCT/US2001/027795 WO2002040451A2 (en) 2000-11-17 2001-11-02 Lactam compound

Publications (2)

Publication Number Publication Date
AU2002224321A1 AU2002224321A1 (en) 2002-08-01
AU2002224321B2 true AU2002224321B2 (en) 2006-10-19

Family

ID=22944436

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002224321A Ceased AU2002224321B2 (en) 2000-11-17 2001-11-02 Lactam compound
AU2432102A Pending AU2432102A (en) 2000-11-17 2001-11-02 Lactam compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2432102A Pending AU2432102A (en) 2000-11-17 2001-11-02 Lactam compound

Country Status (33)

Country Link
US (1) US20040248878A1 (enExample)
EP (1) EP1353910B1 (enExample)
JP (1) JP4116431B2 (enExample)
KR (1) KR20030045194A (enExample)
CN (2) CN101624372A (enExample)
AR (1) AR031356A1 (enExample)
AT (1) ATE362919T1 (enExample)
AU (2) AU2002224321B2 (enExample)
BR (1) BR0115424A (enExample)
CA (1) CA2425497C (enExample)
CY (1) CY1106682T1 (enExample)
CZ (1) CZ20031340A3 (enExample)
DE (1) DE60128587T2 (enExample)
DK (1) DK1353910T3 (enExample)
DZ (1) DZ3454A1 (enExample)
EA (1) EA006919B1 (enExample)
EC (1) ECSP034598A (enExample)
ES (1) ES2286162T3 (enExample)
HR (1) HRP20030385A2 (enExample)
HU (1) HUP0301862A3 (enExample)
IL (1) IL155275A0 (enExample)
MX (1) MXPA03004250A (enExample)
MY (1) MY141607A (enExample)
NO (1) NO325217B1 (enExample)
PE (1) PE20020798A1 (enExample)
PL (1) PL211018B1 (enExample)
PT (1) PT1353910E (enExample)
SK (1) SK287794B6 (enExample)
SV (1) SV2003000741A (enExample)
TW (1) TWI235151B (enExample)
UA (1) UA77165C2 (enExample)
WO (1) WO2002040451A2 (enExample)
ZA (1) ZA200303411B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
ATE441417T1 (de) 2002-12-20 2009-09-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
ES2413705T3 (es) 2005-04-08 2013-07-17 Daiichi Sankyo Company, Limited Derivado de piridilmetilsulfona
JP5198877B2 (ja) 2006-01-31 2013-05-15 株式会社エーピーアイ コーポレーション ベンゾアゼピノン類の製造方法
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
AU2021244215A1 (en) 2020-03-26 2022-10-13 Seagen Inc. Methods of treating multiple myeloma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
EP1230220A1 (en) * 1999-11-09 2002-08-14 Eli Lilly And Company Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS

Also Published As

Publication number Publication date
NO20032215D0 (no) 2003-05-15
SV2003000741A (es) 2003-01-13
JP4116431B2 (ja) 2008-07-09
ECSP034598A (es) 2003-06-25
WO2002040451A3 (en) 2003-08-28
HRP20030385A2 (en) 2003-08-31
PE20020798A1 (es) 2002-09-06
DK1353910T3 (da) 2007-09-10
ZA200303411B (en) 2004-08-02
KR20030045194A (ko) 2003-06-09
EA200300579A1 (ru) 2003-12-25
HUP0301862A2 (hu) 2003-09-29
NO20032215L (no) 2003-07-16
CN100516047C (zh) 2009-07-22
TWI235151B (en) 2005-07-01
US20040248878A1 (en) 2004-12-09
JP2004521084A (ja) 2004-07-15
UA77165C2 (en) 2006-11-15
DE60128587T2 (de) 2008-01-31
MY141607A (en) 2010-05-31
NO325217B1 (no) 2008-02-25
SK287794B6 (sk) 2011-10-04
ATE362919T1 (de) 2007-06-15
CA2425497A1 (en) 2002-05-23
CA2425497C (en) 2010-08-17
CN1575282A (zh) 2005-02-02
EA006919B1 (ru) 2006-04-28
CZ20031340A3 (cs) 2004-06-16
AR031356A1 (es) 2003-09-17
WO2002040451A2 (en) 2002-05-23
EP1353910A2 (en) 2003-10-22
CN101624372A (zh) 2010-01-13
SK5432003A3 (en) 2004-09-08
MXPA03004250A (es) 2003-09-22
PL211018B1 (pl) 2012-03-30
DE60128587D1 (de) 2007-07-05
PT1353910E (pt) 2007-08-20
BR0115424A (pt) 2003-10-21
PL360991A1 (en) 2004-09-20
EP1353910B1 (en) 2007-05-23
AU2432102A (en) 2002-05-27
CY1106682T1 (el) 2012-05-23
IL155275A0 (en) 2003-11-23
DZ3454A1 (fr) 2002-05-23
ES2286162T3 (es) 2007-12-01
HUP0301862A3 (en) 2007-09-28

Similar Documents

Publication Publication Date Title
CA2427227C (en) Lactam compound
EP1353910B1 (en) Lactam compound
AU2002243192A1 (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
AU2002224321A1 (en) Lactam compound
JP2004521084A5 (enExample)
US7468365B2 (en) Lactam compound
EP1345955B1 (en) Lactam dipeptide and its use in inhibiting beta-amyloid peptide release
CA2390376A1 (en) .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis
US20040077627A1 (en) Lactam compound
NZ525365A (en) Lactam compound
HK1059731B (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired